Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-5 criteria for MA use disorder~* Be fluent in English and able to understand the consent form~Exclusion Criteria:~* Have an alcohol use disorder or report binge drinking (\>7 drinks for women and \>14 drinks for men)~* Have a greater than mild substance use disorder on any other illicit substance~* Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)~* Are currently taking medications with known drug interactions with SUVO (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and any sedative)~* Are pregnant or breast feeding~* BMI \> 30 (women only)~* Have a current DSM-5 psychiatric disorder or neurological disease requiring on-going treatment that would make participation unsafe~* Have history of seizure disorder~* Have a head injury with loss of consciousness in the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 week Placebo then 1 week SUVO (Type: EXPERIMENTAL): After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
- 1 week SUVO then 1 week Placebo (Type: EXPERIMENTAL): After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).